Abstract
Progressive multifocal leukoencephalopathy (PML) is a rare but devastating demyelinating disease of the central nervous system caused by the reactivation of the JC virus (JCV). While most commonly associated with HIV/AIDS, it is increasingly observed in organ transplant recipients due to potent immunosuppressive regimens. This report describes a 58-year-old female kidney transplant recipient who developed PML 47 months post-transplantation. Despite the typically fatal nature of the disease, a significant reduction in immunosuppressive therapy led to near-complete clinical and radiological resolution, highlighting a critical management strategy for this patient population.
Introduction: The Problem of JCV Reactivation
PML is caused by the JC virus, a common polyomavirus that remains latent in the kidneys and lymphoid tissues of approximately 46–68% of the healthy population. In the setting of severe cellular immunodeficiency, the virus reactivates and targets oligodendrocytes, the cells responsible for producing myelin in the brain. This leads to progressive neurological dysfunction.
For transplant recipients, PML presents a unique "therapeutic tightrope." There are currently no effective antiviral medications for JCV; the only proven treatment is immune reconstitution. However, restoring the patient's immune system to fight the virus directly increases the risk of acute rejection and loss of the transplanted organ.
Case Presentation
A 58-year-old female, who had received an unrelated living kidney graft 47 months prior, presented with an abrupt onset of vertigo, diplopia (double vision), and paraesthesia on her right side. Her initial induction therapy had included anti-thymocyte globulin (ATG), followed by a maintenance regimen of mycophenolate mofetil (MMF), tacrolimus, and prednisolone.
As the patient's condition deteriorated over two months, she became bedridden, disoriented, and incontinent. Analysis of her cerebrospinal fluid (CSF) revealed hyperproteinemia and lymphocytosis, while flow cytometry showed a severely depressed CD4+ T-cell count (17%), creating an "AIDS-like" immunological state despite standard drug dosing.
Diagnosis and Management
While CT scans are often unremarkable in early PML, MRI is the gold standard for visualization. In this case, T2-weighted and FLAIR sequences identified widespread, non-enhancing hyperintense lesions in the white matter, specifically within the brainstem and thalamus.
Given the high probability of PML, clinicians opted for a drastic reduction in immunosuppression. MMF and tacrolimus dosages were significantly tapered to allow for immune recovery. This intervention was closely monitored alongside graft function (creatinine levels) to balance the risk of rejection against the neurological threat.
Key Results and Discussion
The patient showed remarkable recovery. Within 12 months of the dose reduction, most neurological symptoms had abated, and follow-up MRIs demonstrated a "near complete resolution" of the white matter lesions. Her CD4+ percentage rose to 22%, and while her kidney function temporarily fluctuated, it eventually stabilized with an eGFR of 30–35 mL/min.
Insights from Literature
- Delayed Onset: Unlike other organ transplants where PML often appears within 24 months, kidney recipients show a longer median time to onset (30 months). This case, appearing at 47 months, emphasizes the need for long-term vigilance.
- The Role of MRI: This case reinforces that clinical and radiological regression following immune restoration can be sufficient for diagnosis when invasive brain biopsies are too risky.
- Immune Monitoring: The patient's severe lymphopenia suggests that standard therapeutic drug monitoring of blood levels may not fully capture a patient's true level of cellular immune deficiency.
Conclusion
PML must be considered in the differential diagnosis of any transplant recipient presenting with unexplained neurological or psychiatric symptoms. While potentially fatal, this case demonstrates that minimizing immunosuppressive therapy can lead to the regression of PML and the preservation of graft function. Future research should focus on identifying biomarkers to predict JCV reactivation before the onset of irreversible brain damage.
Summary updated